Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Page 1
Hypoxia-Mimetic CoCl2 Agent Enhances Pro-Angiogenic Activities in Ovine Amniotic Epithelial Cells-Derived Conditioned Medium.
Di Mattia M, Mauro A, Delle Monache S, Pulcini F, Russo V, Berardinelli P, Citeroni MR, Turriani M, Peserico A, Barboni B. Di Mattia M, et al. Among authors: peserico a. Cells. 2022 Jan 28;11(3):461. doi: 10.3390/cells11030461. Cells. 2022. PMID: 35159271 Free PMC article.
On the contrary, CoCl(2) treatment promoted a significant short-term release of angiogenic chemokines in culture media (CM). The enrichment in bio-active factors was confirmed by the ability of CoCl(2)-derived CM to induce HUVEC growth and the cells' organization in tubule …
On the contrary, CoCl(2) treatment promoted a significant short-term release of angiogenic chemokines in culture media (CM). The enri …
Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis).
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F; “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale); Pigatto PDM. Damiani G, et al. Dermatol Ther. 2019 Nov;32(6):e13121. doi: 10.1111/dth.13121. Epub 2019 Nov 7. Dermatol Ther. 2019. PMID: 31625221
Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. ...
Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revol …
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C, Di Tommaso S, Loconte DC, Grossi V, Sanese P, Bagnulo R, Susca FC, Forte G, Peserico A, De Luisi A, Bartuli A, Selicorni A, Melis D, Lerone M, Praticò AD, Abbadessa G, Yu Y, Schwartz B, Ruggieri M, Simone C, Resta N. Ranieri C, et al. Among authors: peserico a. Neurogenetics. 2018 May;19(2):77-91. doi: 10.1007/s10048-018-0540-1. Epub 2018 Mar 16. Neurogenetics. 2018. PMID: 29549527 Free PMC article.
We aimed to assess the effects of blocking the upstream pathway of mTOR on PROS patient-derived cells by using ARQ 092, a potent, selective, allosteric, and experimental orally bioavailable and highly selective AKT-inhibitor with activity and long-term tolerability, curren …
We aimed to assess the effects of blocking the upstream pathway of mTOR on PROS patient-derived cells by using ARQ 092, a potent, selective, …
Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
Piaserico S, Osto E, Famoso G, Zanetti I, Gregori D, Poretto A, Iliceto S, Peserico A, Tona F. Piaserico S, et al. Among authors: peserico a. Atherosclerosis. 2016 Aug;251:25-30. doi: 10.1016/j.atherosclerosis.2016.05.036. Epub 2016 May 21. Atherosclerosis. 2016. PMID: 27236353
In this self-controlled, prospective pilot study, we investigated whether a long-term treatment with TNF-alpha inhibitors effective against skin symptoms also improves coronary flow reserve in psoriasis patients (CFR). ...CONCLUSIONS: The present study demonstrates that TN …
In this self-controlled, prospective pilot study, we investigated whether a long-term treatment with TNF-alpha inhibitors effective a …
Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning.
Gisondi P, Amerio P, Amoroso GF, Antonucci VA, Bardazzi F, Buongiorno MR, Bruni P, Campanati A, Caproni M, Carlesimo M, Carrera CG, Cianchino G, Cimmino G, Costanzo A, Cozzani E, Dapavo P, D'amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio AG, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Loconsole F, Longo V, Malagoli P, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Peserico A, Piaserico S, Pistone G, Potenza C, Plumari A, Stingeni L, Strippoli D, Travaglino M, Girolomoni G. Gisondi P, et al. Among authors: peserico a. G Ital Dermatol Venereol. 2013 Dec;148(6 Suppl 1):1-10. G Ital Dermatol Venereol. 2013. PMID: 24675369
RESULTS: In general, the continuous treatment regimen should be preferred in order to achieve a complete and long-term control of psoriasis. However, the treatment could be stopped or the dose reduced in case of complete disease clearance. ...
RESULTS: In general, the continuous treatment regimen should be preferred in order to achieve a complete and long-term control of pso …
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.
Spandonaro F, Ayala F, Berardesca E, Chimenti S, Girolomoni G, Martini P, Peserico A, Polistena B, Puglisi Guerra A, Vena GA, Altomare G, Calzavara Pinton P. Spandonaro F, et al. Among authors: peserico a. BioDrugs. 2014 Jun;28(3):285-95. doi: 10.1007/s40259-014-0084-3. BioDrugs. 2014. PMID: 24567261 Free PMC article.
After the switch to biologic agents, the cost per QALY during the first year of treatment amounts to 28,656.3. CONCLUSION: At least in the short-term, the clinical practice of the specialised Italian centres taking part in the study confirms that switching pati …
After the switch to biologic agents, the cost per QALY during the first year of treatment amounts to 28,656.3. CONCLUSION: At le …
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
BACKGROUND: There are limited long-term, 'real-world' data on ustekinumab, or the effect of dose adjustment in suboptimal responders. ...
BACKGROUND: There are limited long-term, 'real-world' data on ustekinumab, or the effect of dose adjustment in suboptimal responders. …
Current patch test results with the European baseline series and extensions to it from the 'European Surveillance System on Contact Allergy' network, 2007-2008.
Uter W, Aberer W, Armario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A, Bauer A, Ballmer-Weber B, Beliauskiene A, Fortina AB, Bircher A, Brasch J, Chowdhury MM, Coenraads PJ, Schuttelaar ML, Cooper S, Czarnecka-Operacz M, Zmudzinska M, Elsner P, English JS, Frosch PJ, Fuchs T, García-Gavín J, Fernández-Redondo V, Gawkrodger DJ, Giménez-Arnau A, Green CM, Horne HL, Johansen JD, Jolanki R, Pesonen M, King CM, Krêcisz B, Chomiczewska D, Kiec-Swierczynska M, Larese F, Mahler V, Ormerod AD, Peserico A, Rantanen T, Rustemeyer T, Sánchez-Pérez J, Sansom JE, Silvestre JF, Simon D, Spiewak R, Statham BN, Stone N, Wilkinson M, Schnuch A. Uter W, et al. Among authors: peserico a. Contact Dermatitis. 2012 Jul;67(1):9-19. doi: 10.1111/j.1600-0536.2012.02070.x. Epub 2012 Apr 15. Contact Dermatitis. 2012. PMID: 22500724 Free article.
Some allergens tested nationally may be useful future additions to the European baseline series, for example methylisothiazolinone, whereas a few long-term components of the European baseline series, namely primin and clioquinol, no longer warrant routine testing. ...
Some allergens tested nationally may be useful future additions to the European baseline series, for example methylisothiazolinone, whereas …
Skin cancer and other cutaneous disorders in liver transplant recipients.
Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP, Peserico A, De Matteis G, Perissinotto E, Cillo U, Vitale A, Alaibac M, Burra P. Belloni-Fortina A, et al. Among authors: peserico a. Acta Derm Venereol. 2012 Jul;92(4):411-5. doi: 10.2340/00015555-1316. Acta Derm Venereol. 2012. PMID: 22377797 Free article.
Patients who have received liver transplant are at increased risk of skin complications due to long-term immunosuppression regimen. The aim of this study was to analyze the incidence and risk factors of skin complications in liver transplant patients. ...
Patients who have received liver transplant are at increased risk of skin complications due to long-term immunosuppression regimen. T …
20 results